Lapisteride

Lapisteride
Systematic (IUPAC) name
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
Clinical data
Legal status
  • Non-regulated
Routes of
administration		 Oral[1]
Identifiers
CAS Number 142139-60-4 YesY
ATC code None
PubChem CID 9847295
ChemSpider 8023009 YesY
UNII T50SJ23G82 YesY
Chemical data
Formula C29H40N2O3
Molar mass 464.6395 g/mol
  (verify)

Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.

See also

References

  1. ↑ Yada S, Ohya M, Ohuchi Y, et al. (April 2003). "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics 255 (1-2): 69–79. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
  2. 1 2 Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R (December 2000). "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology 10 (8): 593–5. PMID 11125319.
  3. ↑ Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. p. 157. ISBN 978-0-11-322558-3. Retrieved 17 November 2011.
This article is issued from Wikipedia - version of the Tuesday, September 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.